399 related articles for article (PubMed ID: 19375689)
21. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
[TBL] [Abstract][Full Text] [Related]
22. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration.
Yoganathan P; Deramo VA; Lai JC; Tibrewala RK; Fastenberg DM
Retina; 2006; 26(9):994-8. PubMed ID: 17151485
[TBL] [Abstract][Full Text] [Related]
23. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G
Retina; 2006; 26(5):495-511. PubMed ID: 16770255
[TBL] [Abstract][Full Text] [Related]
24. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
Avery RL; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ
Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
[TBL] [Abstract][Full Text] [Related]
25. Intravitreal bevacizumab for choroidal neovascularization caused by AMD (IBeNA Study): results of a phase 1 dose-escalation study.
Costa RA; Jorge R; Calucci D; Cardillo JA; Melo LA; Scott IU
Invest Ophthalmol Vis Sci; 2006 Oct; 47(10):4569-78. PubMed ID: 17003454
[TBL] [Abstract][Full Text] [Related]
26. Intravitreal bevacizumab (Avastin) therapy versus photodynamic therapy plus intravitreal triamcinolone for neovascular age-related macular degeneration: 6-month results of a prospective, randomised, controlled clinical study.
Weigert G; Michels S; Sacu S; Varga A; Prager F; Geitzenauer W; Schmidt-Erfurth U
Br J Ophthalmol; 2008 Mar; 92(3):356-60. PubMed ID: 18303156
[TBL] [Abstract][Full Text] [Related]
27. Bevacizumab and neovascular age related macular degeneration: pathogenesis and treatment.
El-Mollayess GM; Noureddine BN; Bashshur ZF
Semin Ophthalmol; 2011 May; 26(3):69-76. PubMed ID: 21609219
[TBL] [Abstract][Full Text] [Related]
28. Intravitreal bevacizumab in the treatment of neovascular age-related macular degeneration, 6- and 9-month results.
Cleary CA; Jungkim S; Ravikumar K; Kelliher C; Acheson RW; Hickey-Dwyer M
Eye (Lond); 2008 Jan; 22(1):82-6. PubMed ID: 17891059
[TBL] [Abstract][Full Text] [Related]
29. Short-term effectiveness of intravitreal bevacizumab versus ranibizumab injections for patients with neovascular age-related macular degeneration.
Chang TS; Kokame G; Casey R; Prenner J; Feiner L; Anderson N
Retina; 2009 Oct; 29(9):1235-41. PubMed ID: 19934818
[TBL] [Abstract][Full Text] [Related]
30. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
[TBL] [Abstract][Full Text] [Related]
31. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.
Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S
Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764
[TBL] [Abstract][Full Text] [Related]
32. Intravitreal bevacizumab treatment of choroidal neovascularization secondary to age-related macular degeneration.
Spaide RF; Laud K; Fine HF; Klancnik JM; Meyerle CB; Yannuzzi LA; Sorenson J; Slakter J; Fisher YL; Cooney MJ
Retina; 2006 Apr; 26(4):383-90. PubMed ID: 16603955
[TBL] [Abstract][Full Text] [Related]
33. Comparison of 2.5 mg/kg and 5 mg/kg systemic bevacizumab in neovascular age-related macular degeneration: twenty-four week results of an uncontrolled, prospective cohort study.
Geitzenauer W; Michels S; Prager F; Rosenfeld PJ; Kornek G; Vormittag L; Schmidt-Erfurth U
Retina; 2008; 28(10):1375-86. PubMed ID: 18784625
[TBL] [Abstract][Full Text] [Related]
34. Three-year safety and visual acuity results of epimacular 90 strontium/90 yttrium brachytherapy with bevacizumab for the treatment of subfoveal choroidal neovascularization secondary to age-related macular degeneration.
Avila MP; Farah ME; Santos A; Carla L; Fuji G; Rossi J; Nau J
Retina; 2012 Jan; 32(1):10-8. PubMed ID: 21817963
[TBL] [Abstract][Full Text] [Related]
35. Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series.
Iacono P; Parodi MB; Papayannis A; Kontadakis S; Sheth S; Bandello F
Retina; 2011 Oct; 31(9):1841-7. PubMed ID: 21775926
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of intravitreal bevacizumab (Avastin) therapy for early and advanced neovascular age-related macular degeneration.
Krebs I; Lie S; Stolba U; Zeiler F; Felke S; Binder S
Acta Ophthalmol; 2009 Sep; 87(6):611-7. PubMed ID: 18937801
[TBL] [Abstract][Full Text] [Related]
37. Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration.
Ahmadieh H; Taei R; Soheilian M; Riazi-Esfahani M; Karkhaneh R; Lashay A; Azarmina M; Dehghan MH; Moradian S
BMC Ophthalmol; 2007 Jun; 7():10. PubMed ID: 17555600
[TBL] [Abstract][Full Text] [Related]
38. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study.
Michels S; Rosenfeld PJ; Puliafito CA; Marcus EN; Venkatraman AS
Ophthalmology; 2005 Jun; 112(6):1035-47. PubMed ID: 15936441
[TBL] [Abstract][Full Text] [Related]
39. A Phase IIIb study to evaluate the safety of ranibizumab in subjects with neovascular age-related macular degeneration.
Boyer DS; Heier JS; Brown DM; Francom SF; Ianchulev T; Rubio RG
Ophthalmology; 2009 Sep; 116(9):1731-9. PubMed ID: 19643495
[TBL] [Abstract][Full Text] [Related]
40. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
